(COO) The Cooper Companies - Ratings and Ratios
Contact Lenses, Fertility Devices, Intrauterine Devices, Surgical Instruments
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 30.6% |
| Value at Risk 5%th | 45.4% |
| Relative Tail Risk | -9.91% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.44 |
| Alpha | -30.43 |
| CAGR/Max DD | 0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.389 |
| Beta | 0.802 |
| Beta Downside | 0.658 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.17% |
| Mean DD | 14.50% |
| Median DD | 10.52% |
Description: COO The Cooper Companies October 30, 2025
The Cooper Companies (NASDAQ:COO) operates through two distinct businesses: CooperVision, which designs and sells a broad portfolio of contact lenses-including toric, multifocal, and spherical lenses-to address astigmatism, presbyopia, myopia, and other refractive errors across the Americas, Europe, the Middle East, Africa, and Asia-Pacific; and CooperSurgical, which focuses on family- and women-health products such as fertility consumables, intra-uterine contraceptive devices, cryostorage services, and genomic testing, sold to healthcare professionals and institutions worldwide.
In fiscal 2023, CooperVision generated roughly $3.0 billion in revenue, driven by a 12% year-over-year increase in myopia-control lens sales-a segment benefiting from rising myopia prevalence among children and young adults. CooperSurgical contributed about $1.2 billion, with fertility-related services growing at a compound annual growth rate (CAGR) of 9% since 2020, reflecting global demand for assisted-reproductive technologies and expanding cord-blood banking. Both segments are sensitive to macro-economic factors such as discretionary consumer spending, insurance reimbursement policies, and demographic trends (e.g., aging populations increasing demand for presbyopic lenses).
For a deeper quantitative assessment of COO’s valuation dynamics, you may find the ValueRay platform’s analyst tools useful for exploring forward-looking cash-flow models and peer-group benchmarks.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (374.9m TTM) > 0 and > 6% of Revenue (6% = 245.6m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 1.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 24.28% (prev 23.84%; Δ 0.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 816.3m > Net Income 374.9m (YES >=105%, WARN >=100%) |
| Net Debt (2.39b) to EBITDA (945.5m) ratio: 2.53 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (198.1m) change vs 12m ago -1.49% (target <= -2.0% for YES) |
| Gross Margin 65.54% (prev 66.64%; Δ -1.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.12% (prev 31.63%; Δ 1.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.81 (EBITDA TTM 945.5m / Interest Expense TTM 109.1m) >= 6 (WARN >= 3) |
Altman Z'' 4.66
| (A) 0.08 = (Total Current Assets 2.11b - Total Current Liabilities 1.11b) / Total Assets 12.39b |
| (B) 0.62 = Retained Earnings (Balance) 7.64b / Total Assets 12.39b |
| (C) 0.04 = EBIT TTM 525.3m / Avg Total Assets 12.36b |
| (D) 1.75 = Book Value of Equity 7.26b / Total Liabilities 4.16b |
| Total Rating: 4.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 54.24
| 1. Piotroski 6.0pt |
| 2. FCF Yield 2.21% |
| 3. FCF Margin 10.06% |
| 4. Debt/Equity 0.30 |
| 5. Debt/Ebitda 2.53 |
| 6. ROIC - WACC (= -4.34)% |
| 7. RoE 4.54% |
| 8. Rev. Trend 97.26% |
| 9. EPS Trend -81.35% |
What is the price of COO shares?
Over the past week, the price has changed by +6.59%, over one month by +14.45%, over three months by +19.94% and over the past year by -17.29%.
Is COO a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the COO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 87.9 | 7% |
| Analysts Target Price | 87.9 | 7% |
| ValueRay Target Price | 86.9 | 5.8% |
COO Fundamental Data Overview December 07, 2025
P/E Trailing = 39.902
P/E Forward = 17.5439
P/S = 4.0142
P/B = 1.8084
P/EG = 0.9537
Beta = 1.049
Revenue TTM = 4.09b USD
EBIT TTM = 525.3m USD
EBITDA TTM = 945.5m USD
Long Term Debt = 2.43b USD (from longTermDebt, two quarters ago)
Short Term Debt = 47.8m USD (from shortTermDebt, last quarter)
Debt = 2.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.39b USD (from netDebt column, last quarter)
Enterprise Value = 18.64b USD (16.24b + Debt 2.51b - CCE 110.6m)
Interest Coverage Ratio = 4.81 (Ebit TTM 525.3m / Interest Expense TTM 109.1m)
FCF Yield = 2.21% (FCF TTM 411.9m / Enterprise Value 18.64b)
FCF Margin = 10.06% (FCF TTM 411.9m / Revenue TTM 4.09b)
Net Margin = 9.16% (Net Income TTM 374.9m / Revenue TTM 4.09b)
Gross Margin = 65.54% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.41b) / Revenue TTM)
Gross Margin QoQ = 61.10% (prev 65.26%)
Tobins Q-Ratio = 1.50 (Enterprise Value 18.64b / Total Assets 12.39b)
Interest Expense / Debt = 0.97% (Interest Expense 24.4m / Debt 2.51b)
Taxrate = 27.57% (32.2m / 116.8m)
NOPAT = 380.5m (EBIT 525.3m * (1 - 27.57%))
Current Ratio = 1.89 (Total Current Assets 2.11b / Total Current Liabilities 1.11b)
Debt / Equity = 0.30 (Debt 2.51b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.53 (Net Debt 2.39b / EBITDA 945.5m)
Debt / FCF = 5.81 (Net Debt 2.39b / FCF TTM 411.9m)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.02% (Net Income 374.9m / Total Assets 12.39b)
RoE = 4.54% (Net Income TTM 374.9m / Total Stockholder Equity 8.25b)
RoCE = 4.92% (EBIT 525.3m / Capital Employed (Equity 8.25b + L.T.Debt 2.43b))
RoIC = 3.53% (NOPAT 380.5m / Invested Capital 10.79b)
WACC = 7.87% (E(16.24b)/V(18.75b) * Re(8.97%) + D(2.51b)/V(18.75b) * Rd(0.97%) * (1-Tc(0.28)))
Discount Rate = 8.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF Debug] Terminal Value 72.20% ; FCFE base≈322.8m ; Y1≈276.2m ; Y5≈214.6m
Fair Price DCF = 16.79 (DCF Value 3.34b / Shares Outstanding 198.8m; 5y FCF grow -17.55% → 3.0% )
EPS Correlation: -81.35 | EPS CAGR: -24.14% | SUE: 1.63 | # QB: 3
Revenue Correlation: 97.26 | Revenue CAGR: 8.40% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-01-31): EPS=1.03 | Chg30d=+0.024 | Revisions Net=+2 | Analysts=11
EPS current Year (2026-10-31): EPS=4.50 | Chg30d=+0.098 | Revisions Net=-2 | Growth EPS=+9.1% | Growth Revenue=+5.5%
EPS next Year (2027-10-31): EPS=4.89 | Chg30d=+0.083 | Revisions Net=-2 | Growth EPS=+8.8% | Growth Revenue=+5.2%
Additional Sources for COO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle